Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1003 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1003 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase I / Phase II
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Testing combination immunotherapy and targeted drugs in newly diagnosed advanced kidney cancer to assess safety and effectiveness.
06 May 2026 NCT04626479
● Recruiting
The Effects of PeptiStrong and Whey on Muscle Function In Older Adults
Whey protein and PeptiStrong peptides tested to see if they improve muscle strength and function in older people.
06 May 2026 NCT07528469
active not recruiting Mental Health / Psychiatry
Walking Football for Axial Spondyloarthritis
Walking football twice weekly may safely improve mobility, fitness and wellbeing in axial spondyloarthritis patients.
06 May 2026 NCT07414823
active not recruiting Phase III Cardiology / Cardiovascular
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Pelacarsen reduced heart attacks and strokes in patients with heart disease and high lipoprotein(a) levels.
06 May 2026 NCT04023552
● Recruiting Phase III Rheumatology
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Anifrolumab (an interferon blocker) tested for safety and effectiveness in children with moderate to severe lupus.
06 May 2026 NCT05835310
active not recruiting Respiratory / COPD / Asthma
Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)
Testing whether a drug that increases C-type natriuretic peptide levels reduces fluid leak in experimental skin blisters, as a potential treatment for severe lung…
06 May 2026 NCT05600062
active not recruiting Oncology
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer
Trial testing whether adding targeted radiation therapy to standard cancer drugs improves outcomes in patients with limited lung cancer spread.
06 May 2026 NCT02417662
active not recruiting Phase III
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
Bimekizumab safety study in patients with moderate to severe hidradenitis suppurativa over long-term treatment.
06 May 2026 NCT04901195
active not recruiting Phase I / Phase II
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Testing combined immunotherapy and targeted drugs in patients with advanced kidney cancer who've had previous treatments.
06 May 2026 NCT04626518
● Recruiting Cardiology / Cardiovascular
Improving Patient Assessment After Acute Kidney Injury (AKI)
What is being tested: The trial evaluates whether cystatin C or serum creatinine is a more reliable biomarker for assessing kidney function recovery following…
06 May 2026 NCT07569588
● Recruiting Phase II
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
What is being tested: Surovatamig, a novel subcutaneous therapeutic agent, is being evaluated for its safety, tolerability, pharmacokinetics, and efficacy in treating primary membranous…
06 May 2026 NCT07571746
● Recruiting Phase III
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
What is being tested: Long-term safety and tolerability of iptacopan (LNP023), a complement Factor B inhibitor, in an open-label extension program for patients with…
06 May 2026 NCT04557462
● Recruiting Mental Health / Psychiatry
An Exploration of Sleep Disturbance and Outcomes in TBI (SLEEP-TBI)
What is being tested: The relationship between sleep disturbance (including insomnia, excessive daytime sleepiness, and altered sleep patterns) and clinical outcomes in traumatic brain…
06 May 2026 NCT07120373
● Recruiting EARLY_PHASE1 Respiratory / COPD / Asthma
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis
What is being tested: Linaclotide, a guanylate cyclase-C agonist currently licensed for constipation and IBS-C, is being evaluated as a potential treatment for cystic…
06 May 2026 NCT07569419
● Recruiting Respiratory / COPD / Asthma
Increasing the Use of an Anti-snoring Mouth Guard (Mandibular Advancement Appliance) to Prevent Upper Airway Collapse During Sleep in Patients With Obstructive Sleep Apnoea.
What is being tested: Effectiveness of Mandibular Advancement Appliances (MAA/oral appliances) to mechanically prevent upper airway collapse during sleep in obstructive sleep apnoea patients,…
06 May 2026 NCT04092660
● Recruiting Phase II Cardiology / Cardiovascular
Methods of T Cell Depletion Trial (MoTD)
What is being tested: Three different GvHD prophylaxis strategies following unrelated donor stem cell transplantation: Thymoglobulin, calcineurin inhibitor-based regimens, and sirolimus-based post-transplant cyclophosphamide approaches.…
06 May 2026 NCT04888741
● Recruiting Cardiology / Cardiovascular
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
What is being tested: IMPEDE-FX RapidFill, an adjunctive embolic agent used alongside standard endovascular aneurysm repair (EVAR) stent grafts, to promote AAA sac shrinkage…
06 May 2026 NCT06029660
● Recruiting Phase I Cardiology / Cardiovascular
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
What is being tested: Safety, tolerability, and pharmacokinetics of regadenoson (a vasodilator) administered as a single dose during cardiac magnetic resonance (CMR) stress testing…
06 May 2026 NCT04604782
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Drug Being Tested: BMS-986365 is being evaluated against standard investigator-selected therapies in a comparative efficacy and safety trial for metastatic castration-resistant prostate cancer (mCRPC).…
06 May 2026 NCT06764485
● Recruiting Phase III Oncology
Neoadjuvant Darovasertib in Primary Uveal Melanoma
What is being tested: Darovasertib, a PKC412 inhibitor, administered before surgery (neoadjuvant approach) in patients with primary uveal melanoma to assess efficacy in reducing…
06 May 2026 NCT07015190
● Recruiting Phase II Oncology
Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer
What is being tested: The optimal duration of platinum-based chemotherapy (3 vs 6 cycles) prior to maintenance avelumab immunotherapy in patients with advanced urothelial…
06 May 2026 NCT06892860
● Recruiting Phase II Rheumatology
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
AZD1163 was tested in moderate-to-severe rheumatoid arthritis patients to assess whether it works and is safe.
05 May 2026 NCT07276581
● Recruiting Phase II
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
SAT-3247 tested at two doses versus placebo in children aged 7-10 with muscular dystrophy over 12 weeks to find the best dose and safety…
05 May 2026 NCT07287189
active not recruiting Phase IV Respiratory / COPD / Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Benralizumab improves lung structure and function in severe eosinophilic asthma poorly controlled by standard inhalers.
05 May 2026 NCT03953300
active not recruiting Phase III Infectious Disease
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Daily F/TAF tablet prevents HIV infection in high-risk men and transgender women compared with F/TDF.
05 May 2026 NCT02842086
● Recruiting Diabetes / Metabolic
Scottish Advanced Fetal Research Study
Study examining how maternal smoking, alcohol, drugs and environmental exposures affect fetal development and long-term health outcomes.
05 May 2026 NCT04613583
active not recruiting
How Healthy Are Your Oats?
Study examining nutritional content and how the body absorbs beneficial compounds from a single oat breakfast portion.
05 May 2026 NCT07050680
active not recruiting Phase III
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Belzutifan plus lenvatinib compared to cabozantinib for treating advanced kidney cancer after prior treatment.
05 May 2026 NCT04586231
active not recruiting Phase III Oncology
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
New drug combination tested against standard chemotherapy in advanced lung cancer patients who've had prior immunotherapy and chemotherapy.
05 May 2026 NCT06635824
active not recruiting Phase I / Phase II
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter’s Syndrome or Prolymphocytic Leukemia
A new blood cancer drug (acalabrutinib) is being tested for safety and effectiveness in treating chronic lymphocytic leukaemia.
05 May 2026 NCT02029443
active not recruiting Phase II Oncology
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
ALL-RIC Trial Summary Trial comparing two pre-transplant chemotherapy regimens in older adults with acute lymphoblastic leukaemia to reduce disease relapse without increasing transplant mortality.
05 May 2026 NCT03821610
● Recruiting Phase III Oncology
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
What is being tested: 177Lu-TLX591, a targeted radioligand therapy, is being evaluated in combination with standard of care versus standard of care alone in…
05 May 2026 NCT06520345
● Recruiting Phase II Oncology
INSPIRE: INnovative SABR for Prostate Cancer All IREland
What is being tested: Next generation Stereotactic Ablative Radiotherapy (SABR) with integrated toxicity reduction strategies for low, intermediate, and eligible high-risk prostate cancer, evaluated…
05 May 2026 NCT07552168
● Recruiting Phase II Oncology
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
What is being tested: Disitamab vedotin, a novel antibody-drug conjugate, is being evaluated in combination with other anticancer agents to determine efficacy and safety…
05 May 2026 NCT06157892
● Recruiting Gastroenterology
Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP)
What is being tested: This observational study collects real-world data on the clinical effects and burden of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)…
05 May 2026 NCT07567131
● Recruiting Phase III Gastroenterology
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
What is being tested: Pegozafermin (a FGF21 analogue) at two different dose regimens versus placebo for treating liver fibrosis (stages F2–F3) in adults with…
05 May 2026 NCT06318169
● Recruiting Phase II Infectious Disease
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
What is being tested: AZD4144, an investigational drug being evaluated for its efficacy, safety, and tolerability in treating sepsis-associated acute kidney injury (AKI), a…
05 May 2026 NCT07215702
● Recruiting Phase III Respiratory / COPD / Asthma
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn’s Disease (CD)
What is being tested: Vedolizumab, an anti-inflammatory biologic agent targeting gut-specific integrin α4β7, is being evaluated for efficacy and safety in paediatric patients (children…
05 May 2026 NCT04779320
● Recruiting Phase IV Respiratory / COPD / Asthma
Pediatric Long-Term Follow-up and Rollover Study
What is being tested: Long-term safety and efficacy of dabrafenib (BRAF inhibitor) and/or trametinib (MEK inhibitor) in pediatric patients who have completed prior dabrafenib/trametinib…
05 May 2026 NCT03975829
● Recruiting Phase I Oncology
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
What is being tested: A combination immunotherapy of BNT326 and BNT327 in a dose-finding study to establish safety and efficacy in advanced/metastatic NSCLC across…
05 May 2026 NCT07111520
● Recruiting Cardiology / Cardiovascular
A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries
What is being tested: Lanadelumab, a monoclonal antibody targeting plasma kallikrein, is being evaluated as a preventative treatment for hereditary angioedema (HAE) in the…
05 May 2026 NCT07251933
● Recruiting Phase II Cardiology / Cardiovascular
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
What is being tested: RLY-2608, a mutant-selective PI3Kα inhibitor, is being evaluated for safety and efficacy in treating PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-driven…
05 May 2026 NCT06789913
● Recruiting Cardiology / Cardiovascular
Evaluation of A Clinical Diagnostic Test for CRDS
Test being evaluated: A novel clinical diagnostic test for Calcium Release Deficiency Syndrome (CRDS) caused by RyR2 loss-of-function mutations, designed to replace current cellular-based…
05 May 2026 NCT06188689
● Recruiting Phase III Cardiology / Cardiovascular
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
What is being tested: Omecamtiv mecarbil (CK-1827452), an investigational cardiac myosin activator, is being evaluated to determine if it reduces adverse outcomes including hospitalisation,…
05 May 2026 NCT06736574
● Recruiting Phase I Oncology
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
What is being tested: AZD9574 is being evaluated as both a standalone treatment and in combination with established anti-cancer agents, with assessment of safety,…
05 May 2026 NCT05417594
● Recruiting Phase III Oncology
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
What is being tested: ALLTogether is a master protocol that consolidates evidence-based treatment approaches for acute lymphoblastic leukaemia (ALL) across infants, children, and young…
05 May 2026 NCT04307576
active not recruiting Phase III
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Monthly eye injections of vonaprument tested to slow vision loss in dry age-related macular degeneration with geographic atrophy.
04 May 2026 NCT06510816
● Recruiting Phase III Gastroenterology
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
A new drug called Afimkibart is being tested to see if it safely treats moderate to severe ulcerative colitis better than placebo.
04 May 2026 NCT06588855
active not recruiting Phase III
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
Two-year trial testing EYP-1901 against aflibercept for wet age-related macular degeneration, with main results at one year.
04 May 2026 NCT06683742
● Recruiting Phase III Gastroenterology
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn’s Disease
New drug afimkibart tested for safely treating moderate-to-severe Crohn's disease in a phase three trial comparing it against placebo.
04 May 2026 NCT06819878